| Objective To investigate the short term efficacy and long-term prognosis of entecavir and adefovir dipivoxil in treatment of patients with hepatitis B cirrhosis. Methods Eighty-six cases of compensatoryhepatitis B cirrhosis patients in our hospital during Sept 2011 to Jan 2015 were randomly divided into entecavir group (n=43) and adefovir group (n=43). Patients in entecavir group were treated with entecavir on the basis of routine treatment and those in adefovir group with adefovir dipivoxil on the basis of routine treatment, both lasting for 48 weeks and followed up for 3 years after treatment. Vierendeel peripheral blood before and after treatment was collected and virology indexes (HBV-DNA load, HBV-DNA negative rate), liver fibrosis index were compared between the two groups. The incidence of adverse drug reactions during the treatment, incidence of adverse outcomes (decompensated cirrhosis, primary liver cancer and all-cause death) during follow-up period were recorded. Results Forty-eight weeks after treatment, the level of HBV-DNA in peripheral blood in entecavir group was lower than that in adefovir group, HBV-DNA negative conversion rate was higher than that in adefovir group, serum levels of PC Ⅲ, Ⅳ-C, LN and HA were lower than those in adefovir group, and the differences of these indexes were statistically significant(P<0.05). During treatment, there was no significant difference in the incidence of adverse drug reactions between the two groups(P>0.05). During the follow-up period, the rate of decompensation, primary liver cancer, all cause death in entecavir group were lower than those in adefovir group, and the difference was statistically significant (P<0.05). Conclusion Compared with adefovir, entecavir is more advantageous in virological response and inhibition of fibrosis process in compensatory liver cirrhosis, which can actively reduce the incidence of bad outcome. |
